In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report), with a price target of $18.00. The company’s shares opened today at $1.89.
Goldstein covers the Healthcare sector, focusing on stocks such as Incyte, Arcus Biosciences, and Autolus Therapeutics. According to TipRanks, Goldstein has an average return of 1.8% and a 37.07% success rate on recommended stocks.
Autolus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $11.00, a 482.01% upside from current levels. In a report released on December 9, Needham also reiterated a Buy rating on the stock with a $7.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Autolus Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.37 million and a GAAP net loss of $42.77 million. In comparison, last year the company had a GAAP net loss of $33.99 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
Read More on AUTL:
- Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
- Autolus Therapeutics 75M share Spot Secondary priced at $2.00
- Autolus Tanks After Pricing of Public Offering
- Autolus Announces Pricing of Public Offering
- Autolus Therapeutics to receive two $35M payments from Blackstone Life Sciences